Acknowledgements This work was supported by Zhang zhiqin, the Taiyuan Center for Disease Control and Prevention of the Taiyuan city, Shanxi Province. References 1. Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF,
Benamouzig R, Breau JL, Proteasome structure Perret GY: Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006, click here 94:1823–1832.PubMedCrossRef 2. Bradshaw AD, Sage EH: SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001, 107:1049–54.PubMedCrossRef 3. Framson PE, Sage EH: SPARC and tumor growth: where the seed meets the soil? J Cell Biochem 2004, 92:679–90.PubMedCrossRef 4. Said N, Motamed K: Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol 2005,167(6):1739–52.PubMedCrossRef 5. Said N, Socha MJ, Olearczyk JJ, Elmarakby AA, Imig JD, Motamed K: Normalization of the ovarian cancer microenvironment by SPARC. Mol Cancer Res 2007, 5:1015–30.PubMedCrossRef
6. Raines EW, Lane TF, Iruela-Arispe ML, Ross R, Sage EH: The extracellular glycoprotein SPARC interacts with platelet-derived growth factor(PDGF)-AB and-BB and inbibits the binding of PDGF to its receptors. Proc Natl Acad Sci USA 1992, 89:1281–5.PubMedCrossRef 7. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL: The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated
GDC-0449 datasheet with the neoplastic progression of human melanoma. J Invest Dermatol 1997, 108:210–4.PubMedCrossRef 8. Hasselaar P, Sage EH: Celecoxib SPARC antagonizes the effect of bFGF on the migration of bovine aortic endothelial cells. J Cell Biochem 1992, 49:272–83.PubMedCrossRef 9. Brennan DJ, Rexhepaj E, O’Brien SL, McSherry E, O’Connor DP, Fagan A, Culhane AC, Higgins DG, Jirstrom K, Millikan RC, Landberg G, Duffy MJ, Hewitt SM, Gallagher WM: Altered cytoplasmic to nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res 2008, 14:2681–9.PubMedCrossRef 10. Koo CL, Kok LF, Lee MY, Wu TS, Cheng YW, Hsu JD, Ruan A, Chao KC, Han CP: Scoring mechanisms of p16INK4a immunohistochemistry based on either independent nucleic stain or mixed cytoplasmic with nucleic expression can significantly signal to distinguish between endocervical and endometrial adenocarcinomas in a tissue microarray study. J Transl Med 2009, 7:25.PubMedCrossRef 11. Zhou S, Wang GP, Liu C, Zhou M: Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer. BMC Cancer 2006, 30:231.CrossRef 12. Gao J, Knutsen A, Arbman G, Carstensen J, Frånlund B, Sun XF: Clinical and biological significance of angiogenesis and lymphangiogenesis in colorectal cancer. Dig Liver Dis 2009,41(2):116–22. Epub 2008 Nov 26PubMedCrossRef 13.